Acumen Pharmaceuticals Q2 2024 GAAP EPS $(0.34) Misses $(0.28) Estimate
Portfolio Pulse from Benzinga Newsdesk
Acumen Pharmaceuticals (NASDAQ:ABOS) reported a Q2 2024 GAAP EPS of $(0.34), missing the analyst consensus estimate of $(0.28) by 21.43%.

August 13, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acumen Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.34), missing the analyst consensus estimate of $(0.28) by 21.43%.
The significant miss on earnings per share (EPS) is likely to negatively impact investor sentiment and could lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100